Ostrich MSEL-neurophysin belongs to the class of two-domain “big” neurophysin as indicated by complete amino acid sequence of the neurophysin/copeptin

Mammalian neurohypophyseal hormones, oxytocin and vasopressin, are known to be synthesized as part of two larger precursors containing, respectively, a VLDV-neurophysin and a MSEL-neurophysin together with its associated glycopeptide. Starting from ostrich neurohypophyses, a “big” neurophysin was isolated and chemically characterized. Following sequence determination of the CNBr-derived fragments and of peptides obtained from trypsin and V8-protease digestion of the oxidized protein, this “big” neurophysin was found to contain an MSEL-neurophysin moiety (94 residues) still covalently associated with the COOH-terminal glycopeptide (38 residues, copeptin). This study demonstrates that the ostrich MSEL-neurophysin sequence closely resembles all known MSEL-neurophysin sequences and that, furthermore, it does not contain the single amino acid insertion shown previously in the ostrich VLDV-neurophysin. It is also shown that the stretch of amino acids, linking the MSEL-neurophysin and the copeptin, is clearly different from its mammalian homologues and lacks the Arg residue normally recognized by the cleaving enzyme. This study also demonstrates that the ostrich copeptin is more closely related to the amphibian copeptin sequence than to its mammalian homologue, leading to the hypothesis that two families of copeptin molecules might exist. Thus, the ostrich MSEL-neurophysin-copeptin molecule is the first “big” neurophysin reported in birds and, together with the guinea pig and amphibian homologues, represents the third example of partial or no neurophysin-copeptin cleavage.     

Complete amino acid sequence of goose VLDV-neurophysin Traces of a putative gene conversion between promesotocin and provasotocin genes

Goose VLDV-neurophysin (mesotocin-associated neurophysin) has been purified from posterior pituitary glands through molecular sieving on Sephadex G-75 and high-pressure reverse-phase liquid chromatography on Nucleosil C-18 columns. Despite apparent molecular mass of unreduced VLDV-neurophysin measured by polyacrylamide gel electrophoresis with sodium dodecylsulfate appeared near 17kDa, this value fell to 11 kDa after reduction with mercaptoethanol, suggesting the existence of a homodimer. Complete amino acid sequence (93 residues) of goose VLDV-neurophysin has been determined. N- and C-terminal sequences of the protein have been established by Edman degradation (microsequencing) and use of carboxypeptidase Y, respectively. Peptides derived from oxidized or carboxamidomethylated neurophysin by trypsin or staphylococcal proteinase hydrolyses have been isolated by high-pressure liquid chromatography and microsequenced, allowing determination of the complete sequence. Comparison within the vertebrate VLDV-neurophysin lineage, namely goose VLDV-neurophysin to mammalian VLDV-neurophysins and to deduced toad VLDV-neurophysin, reveals a residue insertion between positions 66 and 67 in the nonmammalian VLDV-neurophysins. When goose MSEL-neurophysin (vasotocin-associated neurophysin) and goose VLDV-neurophysin are compared to their bovine counterparts, identical substitutions are found in positions 17 (Asn in both goose neurophysins instead of Gly in both ox neurophysins), 18 (Arg instead of Lys), 35 (Tyr instead of Phe), and 41 (Thr instead of Ala). Identity of the sequences 10-74 in both ox neurophysins has been explained by partial gene conversion between oxytocin and vasopressin genes, and identical substitutions in both goose neurophysins might reveal a similar gene conversion between mesotocin and vasopressin genes in birds.     

SYNTHESIS OF ANALOGS OF THE SERUM THYMIC NONAPEPTIDE, “FACTEUR THYMIQUE SERIQUE” (FTS) Part II

New analogs of FTS (Facteur Thymique Sérique), <Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn · OH, a circulating thymic factor, were prepared by replacing the amino acid residues in positions 1, 3, 4, 5, 6 and 3 and 6 together. Five other analogs of C-terminal heptapeptide were prepared by replacing the amino acid residues in position 3 or 6. These peptides were synthesized using conventional synthesis in solution.     

Efficient solid phase synthesis of mixed Thr(P)-, Ser(P)- and Tyr(P)-containing phosphopeptides by “global”“phosphite-triester” phosphorylation*

The synthesis of the mixed Thr(P), Tyr(P)-containing peptide, Ala-Thr(P)-Tyr(P)-Ser-Ala, was accomplished by “phosphite-triester” phosphorylation of the resin-bound Thr Tyr-containing peptide using di-t-butyl N,N-diethylphosphoramidite as the phosphitylation reagent. The pentapeptide-resin was assembled by Fmoc/ solid-phase peptide synthesis with the use of PyBOP® as coupling reagent and the hydroxy-amino acids incorporated as side-chain free Fmoc-Tyr-OH and Fmoc-Thr-OH. “Global” bis-phosphorylation of the peptide-resin was accomplished by treatment with di-t-butyl N,N-diethylphosphoramidite/1H-tetrazole followed by m-chloroperoxybenzoic acid oxidation of the intermediate di-t-butylphosphite triester. Simultaneous peptide-resin cleavage and peptide deprotection was effected by treatment of the peptide-resin with 5% anisole/TFA and gave the Thr(P) Tyr(P)-containing phosphopeptide in high yield and purity. In addition, the tyrosyl residue was found to be phosphitylated in preference to the threonyl residue since the phosphitylation of the pentapeptide-resin using only 1.1 equiv. of di-t-butyl N,N-diethylphosphoramidite gave Ala-Thr-Tyr(P)-Ser-Ala as the major product and both Ala-Thr(P)-Tyr(P)-Ser-Ala and Ala-Thr-Tyr-Scr-Ala as minor products.     

Development and characterization of a 99mTc‐tricarbonyl–labelled estradiol derivative obtained by “Click Chemistry” with potential application in estrogen receptors imaging

Assessment of the presence of estrogen receptors in breast cancer is crucial for treatment planning. With the objective to develop a potential agent for estrogen receptors imaging, we present the development and characterization of a ^99mTc‐tricarbonyl–labelled estradiol derivative. Using ethinylestradiol as starting material, an estradiol derivative bearing a 1,4‐disubstituted 1,2,3‐triazole–containing tridentate ligand system was synthesized by “Click Chemistry” and fully characterized. Labelling with high yield and radiochemical purity was achieved through the formation of a ^99mTc‐tricarbonyl complex. The radiolabelled compound was stable, exhibited moderate binding to plasma protein (approximately 33%) and lipophilicity in the adequate range (logP 1.3 ± 0.1 at pH 7.4). Studies in MCF7 showed promising uptake values (approximately 2%). However, more than 50% of the activity is quickly released from the cell. Biodistribution experiments in normal rats confirmed the expected “in vivo” stability of the radiotracer but showed very high gastrointestinal and liver activity, which is inconvenient for in vivo applications. Taking into consideration the well‐documented influence of the chelating system in the physicochemical and biological behaviour of technetium‐labelled small biomolecules, research will be continued using the same pharmacophore but different complexation modalities of technetium.     

Complete amino acid sequence of a VLDV-type neurophysin from ostrich differs markedly from known mammalian neurophysins

The neurohypophyseal hormones vasopressin and oxytocin are known to be synthesized in eutherian mammals as part of larger precursors containing either MSEL-or VLDV-neurophysins. A neurophysin has been isolated from ostrich neurohypophyses and shown by partial amino acid sequence determination to be related to mammalian VLDV-neurophysin. The present report describes the complete amino acid sequence of this ostrich neurophysin containing 93 residues. This amino acid sequence, the first reported in birds, differs in a remarkable manner from its mammalian homolog. Indeed, it contains a large number of substitutions, including one insertion, distributed throughout the polypeptide chain when compared to known VLDV-neurophysins. Whereas many of these substitutions are localized inside the so-called constant region of the neurophysin, the highest variation can be found in the COOH-terminal region.     

“Carba” peptide bond surrogates Different approaches to Gly-Ψ(CH2-CH2)-d,l-Xaa pseudo-dipeptide units

Racemic “carba” pseudo-dipeptide units such as Gly-Ψ(CH₂-CH₂)-d,l -Xaa were obtained either through the Horner-Emmons condensation of N-tert.-butyloxycarbonyl-βalaninal with the appropriate substituted triethyl phosphonoacetate, or from commercially available 3-carbethoxy-2-piperidone.     

Acidolytic cleavage of tris(alkoxy)benzylamide (PAL) “internal reference” amino acyl (IRAA) anchoring linkages: validation of accepted procedures in solid-phase peptide synthesis (SPPS)

Under the normal conditions of acidolytic cleavage/deprotection of tris(a1koxy)benzylamide (PAL) anchoring linkages in Fmoc solid-phase peptide synthesis (SPPS), product release occurs by a straightforward single-step pathway. A recently reported cleavage of the NH-VH bond of an amino acyl residue adjacent to PAL [see Int. J. Peptide Protein Res. 38 , 146–153 (1991)] could not be confirmed in novel experiments incorporating a double “internal reference” amino acid (IRAA) design. The results of the present work revalidate the widely accepted application of IRAAs to monitor yields in SPPS, and confirm the reliability of PAL methodology for the preparation of C-terminal peptide amides.     

Crystallography-guided discovery of carbazole-based retinoic acid-related orphan receptor gamma-t (RORγt) modulators: insights into different protein behaviors with “short” and “long” inverse agonists

A series of 6-substituted carbazole-based retinoic acid-related orphan receptor gamma-t (RORγt) modulators were discovered through 6-position modification guided by insights from the crystallographic profiles of the “short” inverse agonist 6. With the increase in the size of the 6-position substituents, the “short” inverse agonist 6 first reversed its function to agonists and then to “long” inverse agonists. The cocrystal structures of RORγt complexed with the representative “short” inverse agonist 6 (PDB: 6LOB), the agonist 7d (PDB: 6LOA) and the “long” inverse agonist 7h (PDB: 6LO9) were revealed by X-ray analysis. However, minor differences were found in the binding modes of “short” inverse agonist 6 and “long” inverse agonist 7h. To further reveal the molecular mechanisms of different RORγt inverse agonists, we performed molecular dynamics simulations and found that “short” or “long” inverse agonists led to different behaviors of helixes H11, H11’, and H12 of RORγt. The “short” inverse agonist 6 destabilizes H11’ and dislocates H12, while the “long” inverse agonist 7h separates H11 and unwinds H12. The results indicate that the two types of inverse agonists may behave differently in downstream signaling, which may help identify novel inverse agonists with different regulatory mechanisms.     

Prediction of γ‐turns from amino acid sequences

Abstract: We predicted γ‐turns from amino acid sequences using the first‐order Markov chain theory and enlarged representative data sets corresponding to protein chains selected from the Protein Data Bank (PDB). The following data sets were used for training and deriving the probability values: (1) an initial data set containing 315 protein chains comprising 904 γ‐turns and (2) a later data set in order to include new entries in the PDB, containing 434 protein chains and comprising 1053 γ‐turns. By excluding 93 protein chains that were common to these two training data sets, we generated two mutually exclusive data sets containing 222 and 341 protein chains for testing our predictions. Applying amino acid probability values derived from training data sets on to testing data sets yielded overall prediction accuracies in the range 54–57%. We recommend the use of probability values derived from the data set comprising 315 protein chains that represents more γ‐turns and also provides better predictions.     

A β-turn-like conformation in “reduced” peptides Crystal structures of two dipeptide analogs with Pro-GlyΨ[CH2-NH] sequence

The conformational properties of the “reduced” dipeptides tBuCO-Pro-GlyΨ[CH₂-NH]NRR′(R = H, R = Et; R = R′= Me) greatly depend upon the neutral or protonated state of the “reduced” amide bond. Due to protonation, the quite flexible neutral molecule turns into a very stable conformation resembling a β-turn in both the solid and solute states. The existence of a strong N ⁺—H…O=C interaction closing a 10-membered cycle illustrates the possible specific properties induced by a chemical modification in pseudopeptide analogs.     

Prediction of β‐turns from amino acid sequences using the residue‐coupled model

Abstract: We evaluated the prediction of β‐turns from amino acid sequences using the residue‐coupled model with an enlarged representative protein data set selected from the Protein Data Bank. Our results show that the probability values derived from a data set comprising 425 protein chains yielded an overall β‐turn prediction accuracy 68.74%, compared with 94.7% reported earlier on a data set of 30 proteins using the same method. However, we noted that the overall β‐turn prediction accuracy using probability values derived from the 30‐protein data set reduces to 40.74% when tested on the data set comprising 425 protein chains. In contrast, using probability values derived from the 425 data set used in this analysis, the overall β‐turn prediction accuracy yielded consistent results when tested on either the 30‐protein data set (64.62%) used earlier or a more recent representative data set comprising 619 protein chains (64.66%) or on a jackknife data set comprising 476 representative protein chains (63.38%). We therefore recommend the use of probability values derived from the 425 representative protein chains data set reported here, which gives more realistic and consistent predictions of β‐turns from amino acid sequences.     

Conformations of ψ[CH2NH] pseudopeptides

The cyclic pseudopentapeptide cyclo[Gly-Proψ[CH₂NH]Gly-D-Phe-Pro] and its TFA salt were synthesized by solution methods, and their conformations were studied by NMR spectroscopy in both DMSO-d₆ and CDC₁₃. While intramolecular hydrogen bonding is observed with some conformers, the nature of the solvent and the presence of TFA affects the relative structural rigidities of the compounds. No evidence was found for the ψ[CH₂NH] or ψ[CH₂NH⁺₂] units acting as H donors in this series.     

Complete amino acid sequence of a subunit from rapeseed high molecular weight protein

A subunit (M, 15 600) from the high molecular weight protein from rapeseed was separated and isolated; its purity and homogeneity were ascertained. The subunit was cleaved with cyanogen bromide, trypsin, chymotrypsin, and Staphylococcus aureus V8 protease. The fragments were separated and isolated by polyacrylamide gel electrophoresis, gel filtration, column chromatography on Dowex 1 × 2, and paper electrophoresis. The amino acid compositions of the intact subunit and different fragments obtained from enzymatic and chemical cleavages were determined. The subunit and its fragments were sequenced by manual Edman method. The phenylthiohydantoin amino acids obtained after each step were identified by thin-layer chromatography and ultraviolet spectroscopy. The complete amino acid sequence of the subunit consisting of 125 amino acid residues has been established by the overlapping method.     

Switching Shiga Toxin (Stx) Type from Stx2d to Stx2a but Not Stx2c Alters Virulence of Stx-Producing Escherichia coli (STEC) Strain B2F1 in Streptomycin (Str)-Treated Mice

Shiga toxin (Stx)-producing Escherichia coli (STEC) strain B2F1 produces Stx type 2d, a toxin that becomes more toxic towards Vero cells in the presence of intestinal mucus. STEC that make Stx2d are more pathogenic to streptomycin (Str)-treated mice than most STEC that produce Stx2a or Stx2c. However, purified Stx2d is only 2- or 7-fold more toxic by the intraperitoneal route than Stx2a or Stx2c, respectively. We hypothesized, therefore, that the toxicity differences among Stx2a, Stx2c, and Stx2d occur at the level of delivery from the intestine. To evaluate that hypothesis, we altered the toxin type produced by stx_2d+ mouse virulent O91:H21 clinical isolate B2F1 to Stx2a or Stx2c. Because B2F1 encodes two copies of stx_2d, we did these studies in a derivative of B2F1 in which stx_2d1 was deleted. Although the strains were equivalently virulent to the Str-treated mice at the 10¹⁰ dose, the B2F1 strain that produced Stx2a was attenuated relative to the ones that produced Stx2d or Stx2c when administered at 10³ CFU/mouse. We next compared the oral toxicities of purified Stx2a, Stx2c, and Stx2d. We found that purified Stx2d is more toxic than Stx2a or Stx2c upon oral administration at 4 µg/mouse. Taken together, these studies suggest that Stx2 toxins are most potent when delivered directly from the bacterium. Furthermore, because Stx2d and Stx2c have the identical amino acid composition in the toxin B subunit, our results indicate that the virulence difference between Stx2a and Stx2d and Stx2c resides in the B or binding subunit of the toxins.     

Validity of (−)-[3H]-CGP 12177A as a radioligand for the ‘putative β4-adrenoceptor' in rat atrium

1. We have recently suggested the existence in the heart of a ‘putative β₄-adrenoceptor'' based on the cardiostimulant effects of non-conventional partial agonists, compounds that cause cardiostimulant effects at greater concentrations than those required to block β₁- and β₂-adrenoceptors. We sought to obtain further evidence by establishing and validating a radioligand binding assay for this receptor with (−)-[³H]-CGP 12177A ((−)-4-(3-tertiarybutylamino-2-hydroxypropoxy) benzimidazol-2-one) in rat atrium. We investigated (−)-[³H]-CGP 12177A for this purpose for two reasons, because it is a non-conventional partial agonist and also because it is a hydrophilic radioligand.
2. Increasing concentrations of (−)-[³H]-CGP 12177A, in the absence or presence of 20 μM (−)-CGP 12177A to define non-specific binding, resulted in a biphasic saturation isotherm. Low concentrations bound to β₁- and β₂-adrenoceptors (pK_D 9.4±0.1, B_max 26.9±3.1 fmol mg^-1 protein) and higher concentrations bound to the ‘putative β₄-adrenoceptor'' (pK_D 7.5±0.1, B_max 47.7±4.9 fmol mg⁻¹ protein). In other experiments designed to exclude β₁- and β₂-adrenoceptors, (−)-[³H]-CGP 12177A (1–200 nM) binding in the presence of 500 nM (−)-propranolol was also saturable (pK_D 7.6±0.1, B_max 50.8±7.4 fmol mg⁻¹ protein).
3. The non-conventional partial agonists (−)-CGP 12177A (pK_i 7.3±0.2), (±)-cyanopindolol (pK_i 7.6±0.2), (−)-pindolol (pK_i 6.6±0.1) and (±)-carazolol (pK_i 7.2±0.2) and the antagonist (−)-bupranolol (pK_i 6.6±0.2), all competed for (−)-[³H]-CGP 12177A binding in the presence of 500 nM (−)-propranolol at the ‘putative β₄-adrenoceptor'', with affinities closely similar to potencies and affinities determined in organ bath studies.
4. The catecholamines competed with (−)-[³H]-CGP 12177A at the ‘putative β₄-adrenoceptor'' in a stereoselective manner, (−)-noradrenaline (pK_iH 6.3±0.3, pK_iL 3.5±0.1), (−)-adrenaline (pK_iH 6.5±0.2, pK_iL 2.9±0.1), (−)-isoprenaline (pK_iH 6.2±0.5, pK_iL 3.4±0.1), (+)-isoprenaline (pK_i<1.7), (−)-RO363 ((−)-(1-(3,4-dimethoxyphenethylamino)-3-(3,4-dihydroxyphenoxy)-2-propranol)oxalate, pK_i 5.5±0.1).
5. The inclusion of guanosine 5-triphosphate (GTP 0.1 mM) had no effect on binding of (−)-CGP 12177A or (−)-isoprenaline to the ‘putative β₄-adrenoceptor''. In competition binding studies, (−)-CGP 12177A competed with (−)-[³H]-CGP 12177A for one receptor state in the absence (pK_i 7.3±0.2) or presence of GTP (pK_i 7.3±0.2). (−)-Isoprenaline competed with (−)-[³H]-CGP 12177A for two states in the absence (pK_iH 6.6±0.3, pK_iL 3.5±0.1; % H 25±7) or presence of GTP (pK_iH 6.2±0.5, pK_iL 3.4±0.1; % H 37±6). In contrast, at β₁-adrenoceptors, GTP stabilized the low affinity state of the receptor for (−)-isoprenaline.
6. The specificity of binding to the ‘putative β₄-adrenoceptor'' was tested with compounds active at other receptors. High concentrations of the β₃-adrenoceptor agonists, BRL 37344 ((RR+SS)[4-[2-[[2-(3-chlorophenyl)-2-hydroxy - ethyl]amino]propyl]phenoxy]acetic acid, 6 μM), SR 58611A (ethyl{(7S)-7-[(2R)-2 - (3 - chlorophenyl) - 2 - hydroxyethylamino] - 5,6,7,8 - tetrahydronaphtyl2 - yloxy} acetate hydrochloride, 6 μM), ZD 2079 ((±)-1-phenyl-2-(2-4-carboxymethylphenoxy)-ethylamino)-ethan-1-ol, 60 μM), CL 316243 (disodium (R,R)-5-[2-[2-(3-chlorophenyl)-2-hydroxyethyl-amino]propyl]- 1,3-benzodioxole-2,2-dicarboxylate, 60 μM) and antagonist SR 59230A (3-(2-ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-2S-2-propanol oxalate, 6 μM) caused less than 22% inhibition of (−)-[³H]-CGP 12177A binding in the presence of 500 nM (−)-propranolol. Histamine (1 mM), atropine (1 μM), phentolamine (10 μM), 5-HT (100 μM) and the 5-HT₄ receptor antagonist SB 207710 ((1-butyl-4-piperidinyl)-methyl 8-amino-7-iodo-1,4-benzodioxan-5-carboxylate, 10 nM) caused less than 26% inhibition of binding.
7. Non-conventional partial agonists, the antagonist (−)-bupranolol and catecholamines all competed for (−)-[³H]-CGP 12177A binding in the absence of (−)-propranolol at β₁-adrenoceptors, with affinities (pK_i) ranging from 1.6–3.6 log orders greater than at the ‘putative β₄-adrenoceptor''.
8. We have established and validated a radioligand binding assay in rat atrium for the ‘putative β₄-adrenoceptor'' which is distinct from β₁-, β₂- and β₃-adrenoceptors. The stereoselective interaction with the catecholamines provides further support for the classification of the receptor as ‘putative β₄-adrenoceptor''.

     

Noninvasive imaging of c(RGD)2‐9R as a potential delivery carrier for transfection of siRNA in malignant tumors

The purpose of our study was to develop and evaluate a novel integrin α_vβ₃‐specific delivery carrier for transfection of siRNA in malignant tumors. We adopted arginine‐glycine‐aspartate (RGD) motif as a tissue target for specific recognition of integrin α_νβ₃. A chimaeric peptide was synthesized by adding nonamer arginine residues (9‐arginine [9R]) at the carboxy terminus of cyclic‐RGD dimer, designated as c(RGD)₂‐9R, to enable small interfering RNA (siRNA) binding. To test the applicability of the delivery carrier in vivo, c(RGD)₂‐9R was labeled with radionuclide of technetium‐99m. Biodistribution and γ‐camera imaging studies were performed in HepG2 xenograft‐bearing nude mice. As results, an optimal 10:1 molar ratio of ^99mTc‐c(RGD)₂‐9R to siRNA was indicated by the electrophoresis on agarose gels. ^99mTc‐c(RGD)₂‐9R/siRNA remained stable under a set of conditions in vitro. For in vivo study, tumor radioactivity uptake of ^99mTc‐c(RGD)₂‐9R/siRNA in nude mice bearing HepG2 xenografts was significantly higher than that of control probe (P  < .05). The xenografts were clearly visualized at 4 hours till 6 hours noninvasively after intravenous injection of ^99mTc‐c(RGD)₂‐9R/siRNA, while the xenografts were not visualized at any time after injection of control probe. It was concluded that c(RGD)₂‐9R could be an effective siRNA delivery carrier. Technetium‐99m radiolabeled‐delivery carrier represents a potential imaging strategy for RNAi‐based therapy.     

A fast,simple, and reproducible automated synthesis of [18F]FPyKYNE‐c(RGDyK) for αvβ3 receptor positron emission tomography imaging

[¹⁸ F]FPyKYNE‐c(RGDyK) was successfully synthesized by the Cu(I) catalyzed Huisgen 1,3‐dipolar cycloaddition of alkynes to azides using [¹⁸ F]FPyKYNE as a prosthetic group in an overall radiochemical yield of 12%–18% (decay‐corrected) and >99.5% chemical and radiochemical purities in 125 min including quality control. This simple, fully automated two‐step, two‐reactor approach consists of a quick and convenient purification of the prosthetic group using silica gel cartridges and its subsequent use for the labeling of the azido‐c(RGDyK) peptide via click chemistry.